Evidence map›Paper›PMID 28984304›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2018

Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.

Masashi Miyaoka, Yara Y Kikuti, Joaquim Carreras, Haruka Ikoma, Shinichiro Hiraiwa, Akifumi Ichiki, Minoru Kojima, Kiyoshi Ando, Tomoyuki Yokose, Rika Sakai and 9 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 52 citations in OpenAlex.

  1. Digital and Manual Assessment of Intrafollicular Ki-67,Diagnostics (Basel, Switzerland) · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Measurable Residual Disease Monitoring in Lymphoma.Current hematologic malignancy reports · 2023
    Review
  10. Article
  11. The pathobiology of follicular lymphoma.Journal of clinical and experimental hematopathology : JCEH · 2023
    Article
  12. Article
  13. Follicular lymphoma and marginal zone lymphoma: how many diseases?Virchows Archiv : an international journal of pathology · 2023
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 2 countries.

Masashi MiyaokaDepartment of Pathology, Tokai University School of Medicine, Isehara, Japan.
Yara Y KikutiDepartment of Pathology, Tokai University School of Medicine, Isehara, Japan.
Joaquim CarrerasDepartment of Pathology, Tokai University School of Medicine, Isehara, Japan.
Haruka IkomaDepartment of Pathology, Tokai University School of Medicine, Isehara, Japan.
Shinichiro HiraiwaDepartment of Pathology, Tokai University School of Medicine, Isehara, Japan.
Akifumi IchikiDepartment of Hematology/Oncology, Tokai University, School of Medicine, Isehara, Japan.
Minoru KojimaDepartment of Hematology/Oncology, Tokai University, School of Medicine, Isehara, Japan.
Kiyoshi AndoDepartment of Hematology/Oncology, Tokai University, School of Medicine, Isehara, Japan.
Tomoyuki YokoseDepartment of Pathology, Kanagawa Cancer Center, Yokohama, Japan.ORCID 0000-0002-9403-9592
Rika SakaiDepartment of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Masahiro HoshikawaDepartment of Pathology, St Marianna University School of Medicine, Kawasaki, Japan.
Naoto TomitaDivision of Hematology and Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
Ikuo MiuraDivision of Hematology and Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
Katsuyoshi TakataDepartment of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Tadashi YoshinoDepartment of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Jun TakizawaDepartment of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan.
Silvia BeaDepartment of Pathology and Hematopathology Unit, Hospital Clinic Barcelona, Molecular Pathology Laboratory, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), CIBER de Cancer (CIBERONIC), University of Barcelona, Barcelona, Spain.
Elias CampoDepartment of Pathology and Hematopathology Unit, Hospital Clinic Barcelona, Molecular Pathology Laboratory, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), CIBER de Cancer (CIBERONIC), University of Barcelona, Barcelona, Spain.
Naoya NakamuraDepartment of Pathology, Tokai University School of Medicine, Isehara, Japan.
Tokai University · JPSt. Marianna University School of Medicine · JPCentro de Investigación Biomédica en Red · ESKanagawa Prefectural Hospital Organization · JPOkayama University · JPNiigata University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements are aggressive B-cell lymphomas. Occasional double-hit follicular lymphomas have been described but the clinicopathological features of these tumors are not well known. To clarify the characteristics of double-hit follicular lymphomas, we analyzed 10 cases of double-hit follicular lymphomas and 15 cases of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements for clinicopathological and genome-wide copy-number alterations and copy-neutral loss-of-heterozygosity profiles. For double-hit follicular lymphomas, the median age was 67.5 years (range: 48-82 years). The female/male ratio was 2.3. Eight patients presented with advanced clinical stage. The median follow-up time was 20 months (range: 1-132 months). At the end of the follow-up, 8 patients were alive, 2 patients were dead including 1 patient with diffuse large B-cell lymphoma transformation. Rearrangements of MYC/BCL2, MYC/BCL6, and MYC/BCL2/BCL6 were seen in 8, 1, and 1 cases, respectively. The partner of MYC was IGH in 6 cases. There were no cases of histological grade 1, 4 cases of grade 2, 5 cases of grade 3a, and 1 case of grade 3b. Two cases of grade 3a exhibited immunoblast-like morphology. Immunohistochemistry demonstrated 9 cases with ≥50% MYC-positive cells. There was significant difference in MYC intensity (P=0.00004) and MIB-1 positivity (P=0.001) between double-hit follicular lymphomas and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. The genome profile of double-hit follicular lymphomas was comparable with conventional follicular lymphomas (GSE67385, n=198) with characteristic gains of 2p25.3-p11.1, 7p22.3-q36.3, 12q11-q24.33, and loss of 18q21.32-q23 (P<0.05). In comparison with high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements, double-hit follicular lymphomas had fewer copy-number alterations and minimal common region of gain at 2p16.1 (70%), locus also significant against conventional follicular lymphomas (P=0.0001). In summary, double-hit follicular lymphomas tended to be high-grade histology, high MYC protein expression, high MYC/IGH fusion, and minimal common region of gain at 2p16.1. Double-hit follicular lymphomas seemed to be a different disease from high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements and have an indolent clinical behavior similar to follicular lymphomas without MYC rearrangement.

Indexed as

Gene RearrangementAgedAged, 80 and overFemaleHumansImmunohistochemistryLymphoma, B-CellLymphoma, FollicularMaleMiddle AgedNeoplasm GradingPhenotypeProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-bcl-6Proto-Oncogene Proteins c-mycBCL2 protein, humanBCL6 protein, humanMYC protein, humanProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-bcl-6Proto-Oncogene Proteins c-myc

Identifiers

PMID28984304
OpenAlexW2762091260

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.